Lilly Licenses Stipple Epitope Discovery Programs

Company Stipple Bio; Eli Lilly Event Type Research and exclusive-license agreement (previously missed 16 Nov release) Modality Epitope-guided targeted oncology (multi-modality) Asset Pointillist platform; STP-100 ADC separate Target Undisclosed tumor-specific epitopes Disease Area Oncology Summary Stipple Bio disclosed a multi-target, multi-modality oncology research and license…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *